Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AN2 Therapeutics Provides Update On Epetraborole Ex-U.S. Development Plan In Treatment-Refractory MAC Lung Disease

Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients   Treatment-Refractory MAC Lung Disease Clinical Development Strategy to
byBenzinga Newsdesk
October 6, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients
     
  • Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung Disease
  • Epetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts